SCHEDULE: 683 Capital Discloses 5.47% Stake in Mersana Therapeutics

683 Capital Management, LLC and its affiliates have reported a 5.47% beneficial ownership stake in Mersana Therapeutics, Inc. common stock.

Summary

• 683 Capital Management, LLC, 683 Capital Partners, LP, and Ari Zweiman (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The Reporting Persons collectively beneficially own 273,420 shares of Mersana Therapeutics, Inc. Common Stock.
• This ownership represents approximately 5.47% of the outstanding Common Stock of Mersana Therapeutics, Inc.
• The percentage is based on 4,998,750 shares of Common Stock outstanding as of November 7, 2025, as disclosed in Mersana's Form 10-Q filed on November 14, 2025.
• The filing indicates that the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a factual disclosure of a significant ownership stake by an institutional investor, which is generally perceived as a positive signal of confidence, but does not contain operational or financial performance data to assess sentiment further.

Positives

• An institutional investor, 683 Capital Management, LLC, has taken a significant 5.47% stake in Mersana Therapeutics, Inc., which can be interpreted as a vote of confidence in the company's future prospects.

Future Outlook

N/A

Industry Context

N/A

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor holding over 5% of the company's stock may influence market perception and potentially share price.

Key Dates

Keywords

Mersana Therapeutics, 683 Capital Management, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investment, Biotechnology, Pharmaceuticals